| Literature DB >> 31109847 |
Maria Nikolaou1, Christina Chrysohoou2, Theodosis Anastasios Georgilas3, Gregory Giamouzis4, George Giannakoulas5, Apostolos Karavidas6, Christodoulos Papadopoulos7, Sotirios Patsilinakos8, Dimitrios Tziakas9, John Parissis10.
Abstract
Heart Failure (HF) is a global pandemic with rapidly increasing prevalence. In an attempt to maintain patients well being, the therapeutic interest has expanded to the vicious cycles that confer to HF mortality and morbidity and a number of comorbidities have been targeted. Iron deficiency represents a common comorbid condition that affects outcomes in HF. The treatment of iron deficiency is strongly supported by the cardiologic societies all over the world. Intravenous iron, primarily ferric carboxymaltose, has shown clinical benefit in this setting, irrespective of the anemia status. Practical recommendations though are lacking. In this document, we have tried to cover the practical gap and provide useful details for intravenous iron use.Entities:
Keywords: Anemia; Exercise capacity; Ferritin; Heart failure; Iron deficiency
Year: 2019 PMID: 31109847 DOI: 10.1016/j.ejim.2019.05.011
Source DB: PubMed Journal: Eur J Intern Med ISSN: 0953-6205 Impact factor: 4.487